Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
Disclosures: Nicholas Prescott: Nothing to Disclose, Andres Mansisidor: Nothing to Disclose, Yaron Bram: Nothing to Disclose, Christine Lim: Nothing to Disclose, Viviana Risca: Nothing to Disclose, Yael David: Nothing to Disclose, Robert Schwartz: Miromatrix Inc: Advisor, Lime Therapeutics: Advisor, Otsuka Inc.: Grant/Research Support, Alnylam Pharmaceuticals: Speaking and Teaching, Alnylam Pharmaceuticals: Consultant 722 IMPROVEMENTS IN PRURITUS ARE ASSOCIATED WITH IMPROVEMENTS IN GROWTH IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: DATA FROM THE MARCH-ON TRIAL Alexander Miethke 1 Amal Aqul 2 Chuan-Hao Lin 3 Douglas Mogul 4 Tiago Nunes 4 Jolan Terner-Rosenthal 4 Marshall Baek 4 Pamela Vig 4 Richard Thompson 5 , 1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2 University of Texas Southwestern Medical Center, Dallas, Texas, 3 Children's Hospital Los Angeles, Los Angeles, California, 4 Mirum Pharmaceuticals, Inc., Foster City, California, 5 King's College London, United Kingdom Background: Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders resulting in disrupted bile composition and cholestasis leading to debilitating pruritus, growth deficits, vitamin deficiency, and progressive liver damage
Castelli S, Ciccarone F, Tavian D, Ciriolo MR
A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility
